Should I buy or sell Cipla?

The average broker rating on Cipla is Buy. The breakup of analyst rating is given below - 1 analysts have given a strong sell rating 1 analysts have given a sell rating 1 analysts have given a hold rating 1 analysts have given a buy rating 2 analysts have given a strong buy rating

Is Cipla a good stock to invest in?

Cipla can be analyzed on the following key metrics - TTM P/E: 29.84 Sector P/E: 31.03 Dividend Yield: 0.85 D/E ratio: 0.02

Gainers & Losers

Mon Dec 30 2024 09:51:20

HCL Technologies share price
₹1,933.102.19%

Tech Mahindra share price
₹1,748.352.14%

Sun Pharmaceutical Industr...
₹1,888.851.46%

Indusind Bank share price
₹962.500.94%

Asian Paints share price
₹2,286.500.69%

Active Stocks

Mon Dec 30 2024 09:51:18

Tata Steel share price
₹137.00-1.40%

Adani Power share price
₹558.4010.15%

Vedanta share price
₹437.90-2.93%

Tata Power share price
₹388.75-2.59%

Wipro share price
₹303.75-1.73%

Cipla Corporate Actions

Company Profile

Cipla share price

Sector: Biotechnology & Drugs

Cipla is trading 0.97% upper at Rs 1,520.70 as compared to its last closing price. Cipla has been trading in the price range of 1,526.00 & 1,495.80. Cipla has given 22.07% in this year & 3.35% in the last 5 days.

Cipla has TTM P/E ratio 29.84 as compared to the sector P/E of 31.03.There are 33 analysts who have initiated coverage on Cipla. There are 6 analysts who have given it a strong buy rating & 12 analysts have given it a buy rating. 6 analysts have given the stock a sell rating.

The company posted a net profit of 1,302.53 Crores in its last quarter.

Listed peers of Cipla include Sun Pharmaceutical Industries (1.46%), Divis Laboratories (2.84%), Cipla (0.97%) etc.

Cipla has a 69.08% public holding.The Mutual Fund holding in Cipla was at 17.48% in 30 Sep 2024. The MF holding has decreased from the last quarter. The FII holding in Cipla was at 28.80% in 30 Sep 2024. The FII holding has increased from the last quarter.

1,520.70 +14.55 (0.97%)Updated : Mon 30 Dec, 2024 | 15:22:14

Cipla share price range

Today's Low

1,495.80

Today's High

1,526.00

52 Week Low

1,231.85

52 Week High

1,702.00

Cipla share Key Metrics

Updated on 31 Dec 2024, 01:08 AM IST

Market Cap ( ₹ Cr.)

1,22,870.40

Beta	0.45
Div. Yield (%)	0.85
P/B	4.60
D/E	0.02
Open Price	1,507.15

TTM P/E	29.84
Peg. Ratio	1.40
Sector P/E	31.03
Prev. Close	1,506.15

CIPLA share Key metrics

Cipla stock Analysis

Price Analysis

1 Week	3.35%
3 Months	-8.02%
6 Month	2.86%
YTD	22.07%
1 Year	22.07%

Risk Meter

24%Moderate risk
24%Moderate risk
24%Moderate risk
24%Moderate risk
24%Moderate risk

Recos

Strong Sell
Sell
Hold
Buy
Strong Buy

Analysts' Views

Ratings	Current	1 W Ago	1 M Ago	3 M Ago
Strong Buy	6	6	5	4
Buy	12	12	13	13
Hold	8	8	8	8
Sell	6	6	6	5
Strong Sell	1	1	1	2
Total	33	33	33	32

Technical Trends

Long Term
Considers price movement over the last 6 months

Not Available

Short Term
Considers price movement over the last 1-2 weeks

Not Available

Bearish
Moderately Bearish
Neutral
Moderately Bullish
Bullish

Insight: Trends unavailable at the moment.

Cipla Financials

INCOME
BALANCE SHEET
Cashflow

Annual

Quarterly

Period	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Total Revenue	25,774.09	22,753.12	21,763.34	19,159.59
Selling/ General/ Admin Expenses Total	4,310.04	7,507.04	6,908.86	6,031.69
Depreciation/ Amortization	1,051.02	1,017.83	987.83	1,000.57
Other Operating Expenses Total	6,353.43	511.60	463.91	399.33
Total Operating Expense	20,728.88	19,047.03	18,430.60	15,960.05
Operating Income	5,045.21	3,706.09	3,332.74	3,199.54
Net Income Before Taxes	5,701.90	4,038.35	3,493.27	3,290.06
Net Income	4,121.55	2,801.91	2,516.75	2,404.87
Diluted Normalized EPS	52.77	37.37	33.28	30.35

*All figures in crores except per share values

Detailed CIPLA Financials

Cipla forecast

Income Sheet (In Cr)Net Income Vs Revenue

Returns Metrics (In Cr)ROA Vs ROE

Mutual Fund Ownership

Ownership as on: Tue, 31 Dec, 2024

Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth

Equity

Amount Invested (Cr.)77.02

% of AUM9.01%

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Growth

Equity

Amount Invested (Cr.)405.25

% of AUM8.07%

DSP Healthcare Fund Regular Growth

Equity

Amount Invested (Cr.)255.26

% of AUM7.86%

HDFC Pharma and Healthcare Fund Regular Growth

Equity

Amount Invested (Cr.)113.11

% of AUM7.75%

Kotak Healthcare Fund Regular Growth

Equity

Amount Invested (Cr.)28.71

% of AUM7.08%

View All

Cipla Corporate actions

Board Meetings
AGM
Dividends
Bonus
Split
Rights

Meeting Date	Purpose
29-Oct-24	Quarterly Results
26-Jul-24	Quarterly Results
10-May-24	Audited Results & Final Dividend
25-Jan-24	Quarterly Results
22-Jan-24	Quarterly Results
27-Oct-23	Quarterly Results
26-Jul-23	Quarterly Results
12-May-23	Audited Results & Final Dividend
25-Jan-23	Quarterly Results
04-Nov-22	Quarterly Results

Meeting Date	Announcement On	Purpose
15-Oct-24	17-Sep-24	POM
20-Aug-24	10-May-24	AGM
10-Aug-23	12-May-23	AGM
26-Aug-22	29-Jul-22	AGM
25-Aug-21	27-Jul-21	AGM
27-Mar-21	23-Feb-21	POM

Announcement On	Record Date	Ex-Dividend	Dividend Value
10-May-24	02-Aug-24	02-Aug-24	13
12-May-23	21-Jul-23	21-Jul-23	8.5
27-Jul-22	10-Aug-22	08-Aug-22	5
14-May-21	-	09-Aug-21	5

Detailed CIPLA Corporate actions

Cipla Company profile

ABOUT Cipla

Industry Biotechnology & Drugs
ISIN INE059A01026
BSE Code 500087
NSE Code CIPLA

Cipla Limited is an India-based global pharmaceutical company. The Company is engaged in manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The Company operates through two segments: Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling, and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. Its product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). Its geographical segments include India, the United States, South Africa, and the Rest of the World. It has its network of manufacturing, trading and other incidental operations in India and International markets.

Cipla Management

Umang Vohra Global Chief Executive Officer, Managing Director, Executive Director
Ashish Adukia Global Chief Financial Officer
Sneha Hiranandani Chief Information Officer
Rajendra Chopra Compliance Officer, Company Secretary

FAQs about Cipla share price

Cipla is trading at 1520.70 as on Mon Dec 30 2024 09:52:14. This is 0.97% upper as compared to its previous closing price of 1506.15.

The market capitalization of Cipla is 122870.40 Cr as on Mon Dec 30 2024 09:52:14.

The average broker rating on Cipla is Buy. The breakup of analyst rating is given below -

6 analysts have given a strong buy rating
12 analysts have given a buy rating
8 analysts have given a hold rating
6 analysts have given a sell rating
1 analysts have given a strong sell rating

The 52 wk high for Cipla is 1702.00 whereas the 52 wk low is 1231.85

Cipla can be analyzed on the following key metrics -

TTM P/E: 29.84
Sector P/E: 31.03
Dividend Yield: 0.85%
D/E ratio: 0.02

Cipla reported a net profit of 4121.55 Cr in 2024.

Trending Stocks

HCL Technologies share price

1,933.10+41.45(2.19%)

Tech Mahindra share price

1,748.35+36.55(2.14%)

Sun Pharmaceutical Industries share price

1,888.85+27.15(1.46%)

Tata Motors share price

732.65-17.90 (-2.38%)

Wipro share price

303.75-5.35 (-1.73%)

Home Markets Premium Instant Loan Mint Shorts

Cipla share price

Cipla share price range

Cipla share Key Metrics

Cipla stock Analysis

Technical Trends

Long Term
Considers price movement over the last 6 months

Short Term
Considers price movement over the last 1-2 weeks

Cipla share price news

Stocks to buy for long term: Bharti Airtel, Ambuja Cements, Cipla among Axis Securities’ New Year stock picks for 2025

Weight-loss drugs: A game changer for India’s top pharma companies

Stocks to buy: Raja Venkatraman recommends three stocks for today—19 December

Shares to buy: Prashanth Tapse of Mehta Equities suggests these three stocks to buy in the short term - December 2024

InCred Equities lowers Nifty 50 target to 25,327 amid stock market crash, recommends these high-conviction stocks

Cipla Financials

Cipla forecast

Cipla Technical

Cipla Futures and Options

Share Price

Open Interest

Cipla Shareholding

Shareholding Pattern

Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Growth

DSP Healthcare Fund Regular Growth

HDFC Pharma and Healthcare Fund Regular Growth

Kotak Healthcare Fund Regular Growth

Cipla Corporate actions

Cipla Company profile

ABOUT Cipla

Cipla Management

FAQs about Cipla share price

Cipla Quick Links

Equity Quick Links

Cipla share price

Cipla share price range

Cipla share Key Metrics

Cipla stock Analysis

Long TermConsiders price movement over the last 6 months

Short TermConsiders price movement over the last 1-2 weeks

Cipla Financials

Cipla forecast

Cipla Technical

Cipla Futures and Options

Share Price

Open Interest

Cipla Shareholding

Shareholding Pattern

Cipla Corporate actions

Cipla Company profile

ABOUT Cipla

Cipla Management

FAQs about Cipla share price

Cipla Quick Links

Equity Quick Links

Wait for it…

Wait for it…

Long Term
Considers price movement over the last 6 months

Short Term
Considers price movement over the last 1-2 weeks